SCHEDULE: Versant Entities Reduce Stake in LENZ Therapeutics, Inc. Through Recent Stock Sales
Beneficial Ownership Amendment
Versant Venture Capital VI, L.P. has significantly reduced its beneficial ownership in LENZ Therapeutics, Inc. through two recent stock sales totaling over $12.5 million.
Summary
- Versant Venture Capital VI, L.P. (Versant VI) sold 200,000 shares of LENZ Therapeutics, Inc. common stock on June 27, 2025, at a weighted average price of $30.465 per share, generating approximately $6,093,000.00 in proceeds.
- Versant VI further sold 191,376 shares of common stock on July 10, 2025, at a price of $34.00 per share, for aggregate proceeds of approximately $6,506,784.00.
- Following these transactions, Versant VI beneficially owns 1,575,899 shares, representing 5.6% of the common stock outstanding.
- Versant Vantage II, L.P. beneficially owns 842,162 shares, representing 3.0% of the common stock outstanding.
- Versant Venture Capital VII, L.P. beneficially owns 1,118,446 shares, representing 4.0% of the common stock outstanding, which includes 70,534 shares issuable upon warrant exercise.
- The percentages of class represented are based on 28,146,154 shares of common stock outstanding as of May 1, 2025, as reported in LENZ Therapeutics, Inc.'s Form 10-Q for the quarter ended March 31, 2025, filed on May 7, 2025, with an adjustment for Versant VII's warrant shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of ownership changes and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership amendment.
Industry Context
This filing is a standard disclosure of changes in significant beneficial ownership by institutional investors, reflecting portfolio management decisions rather than broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Changes in significant ownership by institutional investors can influence market perception and trading dynamics. The reduction in stake by Versant VI might be interpreted differently by various investors.
Key Dates
| Date | Description |
|---|---|
| 2021-07-09 | Original Schedule 13D filing date by certain Reporting Persons. |
| 2023-11-17 | Amendment No. 1 to the Schedule 13D filed. |
| 2024-03-25 | Amendment No. 2 to the Schedule 13D filed. |
| 2024-11-08 | Amendment No. 3 to the Schedule 13D filed. |
| 2025-05-01 | Date as of which 28,146,154 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-05-07 | Date the Issuer's quarterly report on Form 10-Q for the quarter ended March 31, 2025, was filed with the SEC. |
| 2025-06-12 | Amendment No. 4 to the Schedule 13D filed. |
| 2025-06-24 | Amendment No. 5 to the Schedule 13D filed. |
| 2025-06-27 | Versant Venture Capital VI, L.P. sold 200,000 shares of Common Stock. |
| 2025-07-10 | Date of event requiring this filing; Versant Venture Capital VI, L.P. sold 191,376 shares of Common Stock. |
| 2025-07-14 | Signature date of the Amendment No. 6 filing. |
Keywords
LENZ Therapeutics, Versant, Beneficial Ownership, Stock Sale, SEC Filing, Schedule 13D, Institutional Investor, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.